Analyst Price Targets — LUNG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 28, 2025 12:42 pm | — | Lake Street | $4.00 | $2.42 | TheFly | Pulmonx price target lowered to $4 from $8 at Lake Street |
| July 31, 2025 9:05 am | Jason Bednar | Piper Sandler | $2.50 | $3.15 | TheFly | Pulmonx downgraded to Neutral from Overweight at Piper Sandler |
| October 31, 2024 7:39 am | Jason Bednar | Piper Sandler | $10.00 | $6.79 | TheFly | Pulmonx price target lowered to $10 from $12 at Piper Sandler |
| August 1, 2024 8:39 am | William Plovanic | Canaccord Genuity | $16.00 | $7.42 | TheFly | Pulmonx price target raised to $16 from $15 at Canaccord |
| June 4, 2024 8:11 am | Frank Takkinen | Loop Capital Markets | $12.00 | $7.00 | StreetInsider | Lake Street Capital Markets Starts Pulmonx Corp. (LUNG) at Buy |
| January 6, 2023 10:15 am | — | Morgan Stanley | $9.50 | $7.88 | Benzinga | Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $9.5 |
| December 12, 2022 10:17 am | — | Wells Fargo | $6.00 | $6.22 | Benzinga | Wells Fargo Maintains Equal-Weight on Pulmonx, Lowers Price Target to $6 |
| December 12, 2022 7:34 am | — | Citigroup | $10.00 | $5.88 | Benzinga | Citigroup Upgrades Pulmonx to Buy, Lowers Price Target to $10 |
| July 18, 2022 9:44 am | — | Stifel Nicolaus | $20.00 | $16.37 | Benzinga | Stifel Maintains Buy on Pulmonx, Lowers Price Target to $20 |
| July 15, 2022 12:03 pm | — | Morgan Stanley | $19.00 | $16.21 | Benzinga | Morgan Stanley Maintains Equal-Weight on Pulmonx, Lowers Price Target to $19 |
Latest News for LUNG
REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT /…
Pulmonx Corporation (NASDAQ: LUNG - Get Free Report) has received an average recommendation of "Hold" from the eight research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average
Pulmonx Corporation (LUNG) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.33 per share a year ago.
Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript
REDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LUNG.
U.S. House Trading
No House trades found for LUNG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.